Khoury JD, Solary E, Abra O, Akkari Y, Alaggio R, Apperley JF, et al. Fifth edition of the World Health Organization classification of hemolymphoid tumors: myeloid and histiocytic/dendritic neoplasms. leukemia. 2022;36:1703–1719.
Google Scholar
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. blood. 2022;140:1200–1228.
Google Scholar
Patnaik MM, Teferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification, and management. J hematol. 2024;99:1142–1165.
Google Scholar
Tefferi A, Fathima S, Abdelmagid M, Alsugair A, Aperna F, Rezasoltani M, et al. BLAST: A globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia. blood. 2025;146:874-886.
Patnaik MM, Wassie EA, Lasho TL, Hanson CA, Ketterling R, Tefferi A. Blast transformation in chronic myelomonocytic leukemia: risk factors, genetic characteristics, survival, and treatment outcome. J hematol. 2015;90:411–416.
Google Scholar
Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic pathology in risk assessment of patients with chronic myelomonocytic leukemia. blood. 2016;128:1408–1417.
Google Scholar
Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, et al. WHO-defined Mayo prognostic model for chronic myelomonocytic leukemia: ASXL1 and spliceosomal component mutations and consequences. leukemia. 2013;27:1504–1510.
Google Scholar
Patnaik MM, Itzykson R, Lasho T, Kosmider O, Finke C, Hanson C, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. leukemia. 2014;28:2206–2212.
Google Scholar
He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, et al. Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations in acute myeloid leukemia and classifies FLT3 internal tandem duplication allele ratios: a comparative study with standard fragment analysis. Mod Pasol. 2020;33:334–343.
Google Scholar
Castaño-Diez S, López-Guerra M, Zugasti I, Calbo X, Schultz FI, Avendaño A et al. AML typical mutations (CEBPA, FLT3, NPM1) identify high-risk chronic myelomonocytic leukemia independently of CPSS molecules. Blood Adv. 2025;9:39–53.
Google Scholar
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: joint consensus recommendations of the American College of Medical Genetics and Genomics and the Society for Molecular Pathology. Genet Medicine. 2015;17:405–24.
Google Scholar
Mehta N, He R, Vishwanatha DS. Internal standardization of interpretation and reporting of sequence variants in hematologic malignancies. Mor Diagne Sir. 2021;25:517–526.
Google Scholar
McGowan-Jordan J, Hastings R, Moore S. ISCN 2020: an international system for human cytogenomic nomenclature (2020) Cytogenet. Genome Research Institute 2020;161:225–226.
Google Scholar
Kroger N, Zabellina T, Guardiola P, Lunde V, Sierra J, Van Biesen A, et al. Allogeneic stem cell transplantation in adults with chronic myelomonocytic leukemia. Report on behalf of the Chronic Leukemia Working Group of the European Group for Blood and Marrow Transplantation (EBMT). Br J Hematol. 2002;118:67–73.
Google Scholar
Gagelmann N, Badbaran A, Beelen DW, Salit RB, Stölzel F, Rautenberg C, et al. Prognostic score including mutational profile and clinical features for CMML patients undergoing stem cell transplantation. Blood Adv. 2021;5:1760–1769.
Google Scholar
Pofari P, Matin A, Mangaonkar AA, Karr R, Binder M, Alkali A, et al. Prognostic impact and timing considerations of allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer J. 2020;10:121.
Google Scholar
Carratt SA, Braun TP, Coblentz C, Schonrock Z, Callahan R, Curtiss BM, et al. Mutant SETBP1 enhances MAPK pathway activation by NRAS and promotes malignant leukemia. leukemia. 2021;35:3594–3599.
Google Scholar
Vera R, Chiu MC, Huang YJ, Lin TH, Kuo MC, Shi LY. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1 mutant leukemias. J Hematol Oncor. 2019;12:104.
Google Scholar
Montalban-Bravo G, Rodríguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chen K, et al. Impact of co-mutation patterns on disease phenotype and clinical outcome in chronic myelomonocytic leukemia. leukemia. 2024;38:1178–1181.
Google Scholar
Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385.
Google Scholar
Zhao W, Zhang C, Li Y, Li Y, Liu Y, Sun X, et al. Prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis. Hematology. 2022;27:367–378.
Google Scholar
You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, et al. Deficiency of Asxl1 cooperates with oncogenic Nra in mice to reprogram the immune microenvironment and promote leukemic transformation. blood. 2022;139:1066–1079.
Google Scholar
Nousin Farnoud KM, Guglielmelli P, et al. Identification of ultra-high risk genotypes for progression to blast disease redefines molecular-based stratification of myelofibrosis. European Hematology Association, EHA Library, 2025;4160895:PS1820.
Yoshimi A, Lin KT, Wiseman DH, Rahman MA, Pastore A, Wang B et al. Coordinated changes in RNA splicing and epigenetic regulation lead to leukemogenesis. Nature. 2019;574:273–277.
Google Scholar
Peng J, Zuo Z, Fu B, Oki Y, Tang G, Goswami M, et al. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutations. Eur J Hematol. 2016;96:65–71.
Google Scholar
